معرفی
Dirk Schnappinger is a Professor in the Department of Microbiology & Immunology at Weill Cornell Medicine, where he has been a faculty member since 2001. He is affiliated with the Graduate School of Medical Sciences and the Immunology and Microbial Pathogenesis Graduate Program. His research is centered on Mycobacterium tuberculosis, aiming to develop new drugs and vaccines for tuberculosis.
His research focuses on understanding gene expression, bacterial drug resistance, drug tolerance, and cofactor metabolism in M. tuberculosis. The Schnappinger Lab has pioneered genetic methods, including advanced CRISPRi-based gene silencing systems, to manipulate gene function during infection and in vitro. These tools are used to validate novel drug targets and to accelerate the development of faster-acting TB chemotherapies.
Although no article list is provided in the text, his body of work emphasizes molecular and genetic approaches to combat TB, with strong implications for drug mechanism studies and vaccine improvement. His research trends reflect deep integration of chemical genetics, systems biology, and translational microbiology.
- Ellison Medical Foundation New Scholar Award in Global Infectious Diseases (2004–2008)
- Postdoctoral Fellowship from the German Research Council (DFG, 1999–2000)
- Dissertation fellowship from the German Fond of the Chemical Industry (1993–1995)
- Member of the German National Merit Foundation (1989–1992)
Dirk Schnappinger plays a key role in training graduate students through the BCMB Allied Program and the Immunology and Microbial Pathogenesis program. He collaborates extensively with Dr. Sabine Ehrt, with whom he co-leads research and educational initiatives. While specific grants are not listed, his prestigious awards indicate substantial research support. His lab is part of the Tri-I TB Research Group, reflecting a collaborative, multi-institutional approach to tackling tuberculosis.
The Schnappinger Lab is an active research unit within Weill Cornell Medicine, focused on innovative genetic and molecular strategies to understand and combat M. tuberculosis. The lab develops and applies cutting-edge tools such as inducible gene expression systems and CRISPR interference to dissect bacterial physiology during infection.
